AI-Driven BBB Shuttle Collaboration Signals Major Shift in Neuro-Therapeutics
The biotech industry is poised for another leap in neurological therapeutics as Roche and Manifold Bio announce a high-impact strategic collaboration focused on unlocking the difficult barrier of brain delivery. Manifold’s proprietary AI-guided, direct-to-vivo discovery engine designed to test thousands to millions of biologic variants in living systems will be harnessed by Roche to develop a portfolio of next-generation blood-brain-barrier (BBB) shuttles. These shuttles are tailored to carry therapeutic payloads including antibodies, small RNAs, and oligonucleotides into the brain, opening the door to treatments for diseases long considered “undruggable.”
What You Need To Know
- Manifold Bio and Roche form a multi-year research and license agreement to create next-generation blood-brain-barrier (BBB) shuttles for a range of neurological and neurodegenerative disease targets.
- Manifold receives $55 million upfront, plus eligibility for over $2 billion in research, preclinical, clinical and commercial milestone payments, plus tiered royalties.
- Manifold retains the right to apply its BBB shuttle platform to non-licensed targets (outside the Roche partnership), and the option to co-fund one candidate for enhanced royalty participation.
- The collaboration leverages Manifold’s AI-guided, direct-to-vivo “mDesign” engine and its tissue-targeting shuttle portfolio to discover biologics that can cross the BBB enabling delivery of antibodies, oligonucleotides, ASOs to the brain.
Under the terms of the agreement, Manifold will receive an initial payment of $55 million. Beyond that it stands to earn more than $2 billion in aggregate milestones tied to discovery, preclinical, clinical and commercial outcomes, plus ongoing royalties on product sales. In addition, Manifold retains the flexibility to use its shuttle platform for programmes outside the Roche deal, and it has the option to co-fund one candidate in exchange for higher royalty rights.
For Roche, the collaboration represents a strategic reinforcement of its neuro-therapeutics pipeline. While the company has worked on BBB shuttle strategies for over 15 years, the adoption of Manifold’s in-vivo AI platform accelerates the potential to identify more effective delivery vehicles and widen therapeutic reach. “Engineering molecules to safely cross the blood-brain barrier has been a grand challenge for decades,” said Manifold CEO Gleb Kuznetsov.
The science here is notable: Manifold’s mDesign engine accelerates discovery by bypassing traditional in-vitro dependency and pushing variant screening directly in vivo. The science behind Manifold Bio’s mDesign platform is transformative. By shifting from conventional in-vitro experiments to direct in-vivo variant screening, the system generates physiologically relevant data at scale and speeds translation from discovery to clinic.
Through AI-guided design and high-throughput testing, mDesign can pinpoint brain-penetrant molecules early in development. For Roche, this collaboration delivers a critical scientific edge enhancing its capabilities in next-generation brain-shuttle technologies and reinforcing its leadership in the discovery and delivery of targeted biologics for complex neurological diseases.
Related news
Novartis secures triumphant $12 billion takeover of Avidity
The deal signals growing recognition that breakthroughs in neurological disease may depend not only on novel therapeutic payloads but on the delivery systems that get them into the brain. Disorders like Alzheimer’s, Parkinson’s, ALS and other CNS conditions have challenged developers for decades the inability to optimize delivery across the BBB remains a key bottleneck. This alliance between an AI-driven platform company and a global pharma giant may mark a turning point.
That said, risks remain. Designing BBB shuttles that work safely and effectively in humans is complex, and translating early in-vivo success into clinically meaningful outcomes is far from guaranteed. Milestones are large, but so is the technical hurdle. For Manifold, the upside is significant including both near-term cash and longer-term revenue streams via royalties and retained platform rights.
This collaboration is a major strategic move in the neurological therapeutics space. Manifold Bio gains validation and substantial financial backing; Roche strengthens its ability to deliver cutting-edge neuro-treatments. If successful, the partnership could unlock a broader class of brain-targeted medicines and accelerate treatment options for diseases that have long eluded effective therapy.